Advanced in Angiosarcoma of the Scalp

Dr. Dukagjin M. Blakaj

Radiation Oncology
Osu Radiation Oncology LLC
300 W 10th Ave, Ground Floor, 
Columbus, OH 
Accepting New Patients
Advanced in Angiosarcoma of the Scalp
Osu Radiation Oncology LLC
300 W 10th Ave, Ground Floor, 
Columbus, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dukagjin Blakaj is a Radiation Oncologist in Columbus, Ohio. Dr. Blakaj is rated as an Advanced provider by MediFind in the treatment of Angiosarcoma of the Scalp. His top areas of expertise are Laryngeal Cancer, Throat Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Laminectomy, and Gamma Knife Radiosurgery. Dr. Blakaj is currently accepting new patients.

His clinical research consists of co-authoring 122 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Angiosarcoma of the Scalp.

Specialties
Radiation Oncology
Licenses
Radiology in OH
Hospital Affiliations
Ohio State University State Health System
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

OSU RADIATION ONCOLOGY LLC
300 W 10th Ave, Ground Floor, Columbus, OH 43210
Other Locations
OSU RADIATION ONCOLOGY LLC
460 W 10th Ave, Fl 2, Columbus, OH 43210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Procedure, Drug, Radiation
Study Drug: Birinapant
Study Phase: Phase 1
A Group-Mediated Cognitive Behavioral Resistance Exercise Intervention in Head and Neck Cancer Patients Undergoing Chemoradiation Treatment
A Group-Mediated Cognitive Behavioral Resistance Exercise Intervention in Head and Neck Cancer Patients Undergoing Chemoradiation Treatment
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Other, Behavioral
Study Phase: Not Applicable
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
Enrollment Status: Completed
Publish Date: September 20, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

122 Total Publications

Immunotherapy in Initial Treatment of Anaplastic Thyroid Cancer: Evaluation of Overall Survival in a National Cancer Database Study.
Immunotherapy in Initial Treatment of Anaplastic Thyroid Cancer: Evaluation of Overall Survival in a National Cancer Database Study.
Journal: Thyroid : official journal of the American Thyroid Association
Published: September 02, 2025
Similar Doctors
Advanced in Angiosarcoma of the Scalp
Dr. Karl E. Haglund
Radiation Oncology
Advanced in Angiosarcoma of the Scalp
Dr. Karl E. Haglund
Radiation Oncology

Osu Radiation Oncology LLC

300 W 10th Ave, Ground Floor, 
Columbus, OH 
 (0.1 miles away)
614-293-8415
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Karl Haglund is a Radiation Oncologist in Columbus, Ohio. Dr. Haglund is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma of the Scalp. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Adult Soft Tissue Sarcoma, and Small Cell Lung Cancer (SCLC). Dr. Haglund is currently accepting new patients.

Advanced in Angiosarcoma of the Scalp
Dr. David J. Konieczkowski
Radiation Oncology
Advanced in Angiosarcoma of the Scalp
Dr. David J. Konieczkowski
Radiation Oncology

Osu Radiation Oncology LLC

460 W 10th Ave, Fl 2, 
Columbus, OH 
 (0.2 miles away)
614-293-8415
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Konieczkowski is a Radiation Oncologist in Columbus, Ohio. Dr. Konieczkowski is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma of the Scalp. His top areas of expertise are Adult Soft Tissue Sarcoma, Rhabdomyosarcoma Embryonal, Epithelioid Sarcoma, and Mesenchymoma. Dr. Konieczkowski is currently accepting new patients.

Advanced in Angiosarcoma of the Scalp
Dr. John C. Grecula
Radiation Oncology
Advanced in Angiosarcoma of the Scalp
Dr. John C. Grecula
Radiation Oncology

Osu Radiation Oncology LLC

300 W 10th Ave, Ground Floor, 
Columbus, OH 
 (0.1 miles away)
614-293-8415
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Grecula is a Radiation Oncologist in Columbus, Ohio. Dr. Grecula is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma of the Scalp. His top areas of expertise are Adenoid Cystic Carcinoma, Posterior Fossa Tumor, Laryngeal Cancer, Bone Tumor, and Gamma Knife Radiosurgery. Dr. Grecula is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Blakaj's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile